US5741330A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Close vascularization implant material
Assignee: Baxalta GmbH
•
Filing: 1995-06-07
•
Granted: 1998-04-21
•
Expires: 2015-06-07
Abstract
Abstract A device for implantation in a host having a material at an interface between the host and the device, said material having a conformation which results in growth of vascular structures by the host close to the interface.
Inventors
- 👤 James H. Brauker
- 👤 Robert C. Johnson
- 👤 Laura A. Martinson
- 👤 Ronald S. Hill
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 06:09
CPC Classifications
A; A61; A61L; A61L29/00; A61L29/08; A61L29/085; A61F; A61F2/00; A61F2/02; A61F2/022; A61L27/00; A61L27/36; A61L27/38; A61L27/3839; A61L27/50; A61L27/56; A61L29/005; A61L29/14; A61L29/146; A61B; A61B5/00; A61B5/145; A61B5/14532; A61B5/41; A61B5/413; Y; Y10; Y10S; Y10S623/00; Y10S623/92; Y10S623/924; Y10S623/925
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
146 words
A method for implanting a device into host tissue comprising the steps of: (a) providing an implantable device; (b) surrounding at least a portion of the device with a wall comprising: (i) a second zone of semipermeable material which is impermeable to host immune cells; and (ii) a first zone of porous material outside of the second zone having a nominal pore size from about 0.6 to about 20 microns which comprises frames of elongated strands of material that are less than 5 microns in all but the longest dimension wherein said frames define apertures which interconnect to form three dimensional cavities which permit substantially all inflammatory cells migrating into the cavities to maintain a rounded morphology and wherein the first zone promotes vascularization adjacent but not substantially into the first zone upon implantation into the host tissue; and (c) embedding the wall within host tissue.
Claim 2
Independent Claim
146 words
A method for implanting a device into host tissue comprising the steps of: (a) providing an implantable device; (b) surrounding at least a portion of the device with a wall comprising: (i) a second zone of semipermeable material which is impermeable to host immune cells; and (ii) a first zone of porous material outside of the second zone having a nominal pore size from about 0.6 to about 20 microns which comprises frames of elongated strands of material that are less than 5 microns in all but the longest dimension wherein said frames define apertures which interconnect to form three dimensional cavities which permit substantially all inflammatory cells migrating into the cavities to maintain a rounded morphology and wherein the first zone promotes vascularization adjacent but not substantially into the first zone upon implantation into the host tissue; and (c) embedding the wall within host tissue.
Claim 3
Dependent Claim
40 words
The method of claim 1, wherein the porous material comprises a polymer membrane selected from the group consisting of polyethylene, polypropylene, polytetrafluoroethylene (PTFE), cellulose acetate, cellulose nitrate, polycarbonate, polyester, nylon, polysulfone, mixed esters of cellulose, polyvinylidene difluoride, silicone, and polyacrylonitrile.
Claim 4
Dependent Claim
138 words
The method of claim 1, wherein the porous material is selected from the group consisting of: 1) MILLIPORE® Mixed Esters Cellulose, membrane pore size 1.2; 2) MILLIPORE® Mixed Esters Cellulose, membrane pore size 8.0; 3) SATORIOUS®, Cellulose Acetate, membrane pore size 0.8; 4) SATORIOUS®, Cellulose Acetate, membrane pore size 1.2; 5) SATORIOUS®, Cellulose Acetate, membrane pore size 3.0; 6) SATORIOUS®, Cellulose Acetate, membrane pore size 5.0; 7) SATORIOUS®, Cellulose Acetate, membrane pore size 8.0; 8) GORE®, PTFE/Polyester, membrane pore size 1.0; 9) GORE®, PTFE/Polyester, membrane pore size 3.0; 10) GORE®, PTFE/Polyester, membrane pore size 5.0; 11) GORE®, PTFE/Polyester, membrane pore size 10-15; 12) GORE®, PTFE/Polypropylene, membrane pore size 3.0; 13) GELMAN®, VERSAPORE®, membrane pore size 0.8; 14) GELMAN®, VERSAPORE®, membrane pore size 1.2; 15) GELMAN®, VERSAPORE®, membrane pore size 3.0; and 16) GELMAN®, VERSAPORE®, membrane pore size 5.0.
Claim 5
Dependent Claim
12 words
The method of claim 1, wherein the device is an indwelling catheter.
Claim 6
Dependent Claim
28 words
The method of claim 1, wherein the device is an indwelling sensor and wherein the material is permeable to an analyte in the host detectable by the sensor.
Claim 7
Dependent Claim
12 words
The method of claim 1, wherein the device is a breast prosthesis.
Claim 8
Dependent Claim
14 words
The method of claim 1, wherein the device is a container for cellular implantation.
Claim 9
Dependent Claim
16 words
The method of claim 1, wherein the second zone is further impermeable to host immune factors.
References Cited (Backward Citations)
US3967618A
Cited
US4011861A
Cited
US3993072A
Cited
US4374669A
Cited
US4936317A
Cited
US4229838A
Cited
US4306318A
Cited
US4321711A
Cited
US4229836A
Cited
US4352883A
Cited
US4391909A
Cited
US4266999A
Cited
US4298002A
Cited
US4309996A
Cited
US4309776A
Cited
US4576608A
Cited
US4353888A
Cited
GB2095257A
Cited
US4378016A
Cited
US4542539A
Cited
US4475916A
Cited
WO1983003536A1
Cited
US4578191A
Cited
US4505277A
Cited
WO1984001287A1
Cited
US4664669A
Cited
CA1196862A
Cited
US4673566A
Cited
EP0127989A2
Cited
US4689293A
Cited
US4806355A
Cited
US4803168A
Cited
US4670286A
Cited
EP0147939A2
Cited
US4553262A
Cited
US4601893A
Cited
US4508113A
Cited
US4657544A
Cited
US4686098A
Cited
US4712553A
Cited
EP0216149A2
Cited
EP0213908A2
Cited
US4822361A
Cited
US4743252A
Cited
GB2185408A
Cited
US4871366A
Cited
US4804381A
Cited
US4798585A
Cited
US5002572A
Cited
EP0259536A2
Cited
WO1988003785A1
Cited
EP0277678A1
Cited
US4877029A
Cited
US4816339A
Cited
US5026365A
Cited
US4795459A
Cited
US4911717A
Cited
WO1989000742A1
Cited
US4878913A
Cited
US5077215A
Cited
US5035891A
Cited
US4922926A
Cited
WO1989003705A1
Cited
US5182111A
Cited
US4892538A
Cited
US4950483A
Cited
WO1990000888A1
Cited
WO1990002580A1
Cited
EP0359575A2
Cited
US5219361A
Cited
EP0370292A1
Cited
DE4006145A1
Cited
WO1991000119A1
Cited
US5104403A
Cited
US4990138A
Cited
US5002661A
Cited
US5024670A
Cited
WO1991019783A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-04-20 | 2001-10-20 | 2002-04-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-04-20 | 2005-10-20 | 2006-04-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-04-20 | 2009-10-20 | 2010-04-21 | $7700.00 | Window Closed / Lapsed |